An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ

Alexander S. Banks (), Fiona E. McAllister, João Paulo G. Camporez, Peter-James H. Zushin, Michael J. Jurczak, Dina Laznik-Bogoslavski, Gerald I. Shulman, Steven P. Gygi and Bruce M. Spiegelman ()
Additional contact information
Alexander S. Banks: Diabetes and Hypertension, Brigham and Women's Hospital and Harvard Medical School
Fiona E. McAllister: Harvard Medical School
João Paulo G. Camporez: Yale University School of Medicine
Peter-James H. Zushin: Diabetes and Hypertension, Brigham and Women's Hospital and Harvard Medical School
Michael J. Jurczak: Yale University School of Medicine
Dina Laznik-Bogoslavski: Dana-Farber Cancer Institute
Gerald I. Shulman: Yale University School of Medicine
Steven P. Gygi: Harvard Medical School
Bruce M. Spiegelman: Harvard Medical School

Nature, 2015, vol. 517, issue 7534, 391-395

Abstract: Blocking ERK/MAP kinases improves insulin sensitivity thorough a mechanism similar to the actions of the anti-diabetic thiazolidinediones drugs on PPARγ.

Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature13887 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:517:y:2015:i:7534:d:10.1038_nature13887

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature13887

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().